GlassScriptPhysician profile
Heloisa Pentian
NPI 1639751977
$3,626.46
in general payments reported to CMS, 2019-2025
26 companies · $1,690 in 2025
The $1,690 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.89 · 2022: $147 · 2023: $1,253 · 2024: $476 · 2025: $1,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,219 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,218.95 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $562.45 | 2022-2025 | Erleada, Carvykti, Rybrevant |
| Procept Biorobotics Corporation | $520.83 | 2024-2025 | Aquabeam System |
| Axonics, INC. | $379.50 | 2023-2024 | Axonics |
| Astellas Pharma US INC | $230.01 | 2022-2023 | Myrbetriq, Veozah |
| Endo USA, INC. | $218.19 | 2025 | Xiaflex, Aveed, Edex |
| Boston Scientific Corporation | $208.64 | 2023-2025 | Rezum Generator, Axonics, Ams 700 |
| Sumitomo Pharma America, INC. | $187.57 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $174.08 | 2022-2025 | |
| Coloplast Corp | $146.31 | 2023-2024 | Titan |
| Tolmar, INC. | $133.58 | 2023-2025 | Eligard |
| Antares Pharma, INC. | $128.77 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Bayer Healthcare Pharmaceuticals INC. | $98.55 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $96.74 | 2023-2025 | |
| Teleflex LLC | $81.07 | 2025 | Barrigel, Urolift |
| Dendreon Pharmaceuticals LLC | $68.52 | 2025 | Provenge |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $67.53 | 2023 | |
| Ferring Pharmaceuticals INC. | $66.90 | 2025 | Adstiladrin |
| Mission Pharmacal Company | $62.39 | 2023 | Lithostat, Uribel |
| Amarin Pharma, INC. | $43.44 | 2021 | |
| Progenics Pharmaceuticals, INC. | $28.27 | 2025 | |
| Accord Healthcare, INC. | $25.81 | 2025 | |
| Telix Pharmaceuticals | $23.47 | 2025 | Illuccix |
| Karl Storz Endoscopy-America | $22.05 | 2025 | |
| Bluewind Medical | $19.31 | 2025 | |
| Glaxosmithkline, LLC. | $17.45 | 2021 | |
| Myriad Genetic Laboratories, INC. | $15.03 | 2024 | Prolaris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heloisa Pentian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.